Result of AGM
Arecor Therapeutics plc announced that all resolutions were passed at its Annual General Meeting, with the exception of Resolution 5 concerning the re-election of Andrew Richards, which saw 31.82% of votes cast against it. The company will engage with shareholders to understand concerns regarding this resolution. Other resolutions, including the approval of the directors' remuneration report and policy, re-election of other directors, auditor re-appointment, and share allotment authorities, received strong support, with most resolutions passing with over 95% of votes in favour.
Select text to share a quote on X · sign in to keep highlights & notes in your AREC notes
Cambridge, UK, 28 May 2026: Arecor Therapeutics plc (AIM: AREC), a clinical stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases, announces that at its Annual General Meeting held earlier today, all resolutions were passed.
The full text of each resolution was included in the Company's Notice of Annual General Meeting made available on the Company's website.
The number of proxy votes cast for and against each of the resolutions proposed, and the number of proxy votes withheld are shown in the table below.
The Board notes that 31.82% of votes were against Resolution 5. The Board confirms that it will consult and continue to engage with shareholders to understand and discuss their concerns with respect to this resolution.
| Resolution | Votes for | % | Votes against | % | Votes withheld |
|---|---|---|---|---|---|
| Resolution 1 To receive the directors' report, the consolidated financial statements and the auditors' report for the year ended 31 December 2025 | 17,588,351 | 100% | 0 | 0% | 0 |
| Resolution 2 To approve the directors' remuneration report as set out on pages 31 to 36 in the annual report for the year ended 31 December 2025 | 16,756,524 | 95.30% | 827,227 | 4.70% | 4,600 |
| Resolution 3 To approve the director's remuneration policy as set out on pages 32 to 34 in the annual report for the year ended 31 December 2025 | 16,756,524 | 95.30% | 827,227 | 4.70% | 4,600 |
| Resolution 4 To re-elect Sarah Howell as a Director of the Company in accordance with the articles | 16,756,524 | 100.00% | 0 | 0.00% | 831,827 |
| Resolution 5 To re-elect Andrew Richards as a Director of the company in accordance with the articles | 11,952,304 | 68.18% | 5,576,941 | 31.82% | 59,106 |
| Resolution 6 To re-elect Sam Fazeli as a Director of the Company in accordance with the articles | 16,756,524 | 100.00% | 0 | 0.00% | 831,827 |
| Resolution 7 To re-elect Jeremy Morgan as a Director of the Company in accordance with the articles | 16,756,524 | 95.30% | 827,227 | 4.70% | 4,600 |
| Resolution 8 To re-elect Simon Ormiston as a Director of the Company in accordance with the articles | 16,756,524 | 100.00% | 0 | 0.00% | 831,827 |
| Resolution 9 To re-elect David Ellam as a Director of the Company in accordance with the articles | 16,756,524 | 100.00% | 0 | 0.00% | 831,827 |
| Resolution 10 To re-appoint PKF Littlejohn LLP as auditors of the Company | 17,575,001 | 99.93% | 11,500 | 0.07% | 1,850 |
| Resolution 11 To authorise the Directors to agree the auditors' remuneration | 17,588,351 | 100.00% | 0 | 0.00% | 0 |
| Resolution 12 To authorise the allotment of shares | 17,459,642 | 99.59% | 71,453 | 0.41% | 0 |
| Resolution 13 To disapply statutory pre-emption rights | 17,503,110 | 99.53% | 83,391 | 0.47% | 1,850 |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.